Novan completes enrollment in late-stage SB206 studies

Novan (NOVN) has completed the recruitment of ~680 subjects in its two pivotal Phase 3 clinical trials evaluating once-daily topical gel SB206 for the treatment of molluscum contagiosum.

The primary endpoint for both is the proportion of patients achieving complete clearance of all treatable molluscum lesions at week 12 compared to placebo.

Topline data should be available in late Q4 or early Q1 2020.

https://seekingalpha.com/news/3491100-novan-completes-enrollment-late-stage-sb206-studies